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Glomerular podocytes are highly specialized epithelial cells
whose injury in glomerular diseases causes proteinuria. Since
mitochondrial dysfunction is an early event in podocyte
injury, we tested whether a major regulator of oxidative
metabolism and mitochondrial function, the transcriptional
coactivator peroxisome proliferator-activated receptor-c
coactivator 1a (PGC-1a), affects podocyte damage.
Aldosterone-induced injury decreased PGC-1a expression,
and induced mitochondrial and podocyte damage in dose- and
time-dependent manners. The suppression of endogenous
PGC-1a by RNAi caused podocyte mitochondrial damage and
apoptosis while its increase by infection with an adenoviral
vector prevented aldosterone-induced mitochondrial
malfunction and inhibited injury. Overexpression of the silent
mating type information regulation 2 homolog 1, a gene
upstream of PGC-1a, prevented aldosterone-induced
mitochondrial damage and podocyte injury by upregulating
PGC-1a at both the transcriptional and post-translational
levels. Resveratrol, a SIRT1 activator, attenuated aldosterone-
induced mitochondrial malfunction and podocyte injury
in vitro and in aldosterone-infused mice in vivo. Hence,
endogenous PGC-1a may be important for maintenance
of mitochondrial function in podocytes under normal
conditions. Activators of SIRT1, such as resveratol, may be
therapeutically useful in glomerular diseases to promote and
maintain PGC-1a expression and, consequently, podocyte
integrity.
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Glomerular epithelial cells, podocytes, are highly specialized
cells that serve as a crucial component of the glomerular
filtration barrier. Podocytes are composed of a cell body,
major processes and foot processes. The neighboring foot
processes derived from different cell bodies are connected by
a continuous membrane-like structure called the slit
diaphragm and form an interdigitating pattern adhering to
the glomerular basement membrane.1 It is becoming
increasingly clear that podocyte injury leads to proteinuria
and occurs in many glomerular diseases that finally progress
to chronic kidney disease.2,3
Recently, a growing number of studies have shown that
mitochondrial dysfunction (MtD) is associated with many
types of kidney disease.4,5 MtD represents a malfunction in
biochemical processes, resulting from either its own mito-
chondrial DNA (mtDNA) or from nuclear DNA.6 Children
with mitochondrial cytopathies have been reported to
develop focal segmental glomerulosclerosis, and abnormal-
ities of podocyte mitochondria have been detected by
transmission electron microscopy in renal biopsy specimens.7
A rat model of focal segmental glomerulosclerosis also found
that puromycin aminonucleoside nephrosis, the expression of
mtDNA and its encoded proteins were reduced in podo-
cytes.5 Furthermore, our previous studies have demonstrated
that MtD is not just a key mediator, but is important in early
stage processes of podocyte injury (unpublished data).
Peroxisome proliferator-activated receptor-g coactivator
1a (PGC-1a), a transcriptional coactivator of peroxisome
proliferator-activated receptor-g and other nuclear hormone
receptors, is a major regulator of oxidative metabolism and
mitochondrial biogenesis. PGC-1a binds to and coactivates
the transcriptional function of nuclear respiratory factor-1,
which binds specifically to the mitochondrial transcription
factor A (TFAM) promoter, a direct regulator of mtDNA
replication.8 The overexpression of PGC-1a results in a robust
increase in mitochondrial number, cellular respiration, and
intracellular adenosine-50-triphosphate (ATP) concentration
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in a variety of cell types.9,10 In addition, the repression of
PGC-1a expression by a mutant histone deacetylase 5 resulted
in loss of and morphological changes to mitochondria and in
downregulation of mitochondrial enzymes.11
Recently SIRT1 (silent mating type information regulation
2 homolog 1) has been shown to function together with
PGC-1a to regulate mitochondrial biogenesis. SIRT1 is one
of seven mammalian homologs of Sir2 that catalyzes
nicotinamide adenine dinucleotide-dependent protein dea-
cetylation. Several reports have shown that SIRT1 is not just a
histone deacetylase but that SIRT1 can directly interact and
regulate the activity of several transcription factors, such as
p53 and FOXO,12,13 which are involved either in setting a
threshold for apoptosis or in prompting cell repair. Several
lines of evidence indicate that SIRT1-mediated regulation of
PGC-1a activity may have a major role in the metabolic
adaptation to energy metabolism in different tissues.14,15 An
activator of SIRT1, resveratrol (RSV), was recently reported
to promote mitochondrial biogenesis and to protect cells
from metabolic disease through SIRT1-dependent deacetyla-
tion of PGC-1a.15
In the current study, we demonstrate that endogenous
PGC-1a is essential for podocyte maintenance of mitochon-
drial function under normal conditions. Furthermore,
SIRT1/PGC-1a axis activation protect against aldosterone
(Aldo)-induced podocyte injury likely by preventing MtD
and RSV attenuated Aldo-induced MtD and podocyte injury
both in vivo and in vitro.
RESULTS
Aldo-induced MtD and podocyte injury via the
mineralocorticoid receptor (MR)
To evaluate MtD, we used several independent parameters:
reactive oxygen species (ROS) production; mitochondrial
morphology; mitochondrial membrane potential (MMP);
ATP levels; and mtDNA copy number. Aldo induced ROS
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Figure 1 |Aldosterone (Aldo)-induced mitochondrial dysfunction (MtD) in podocytes. (a–d) Aldo-induced reactive oxygen species
(ROS) production of mitochondrial origin. (a) Confluent podocytes in chamber slides were exposed to vehicle or Aldo (100 nmol/l) for 2 h in
the presence of dichlorodihydrofluorescein diacetate (DCFDA). (b, c) Quantitation of 20,70-dichlorofluorescein (DCF) fluorescence by flow
cytometry. In the presence of DCFDA, confluent podocytes were treated with 100 nmol/l Aldo for the indicated periods of time (b) or
incubated with Aldo at the indicated concentrations for 2 h (c). (d) Confluent podocytes were pre-treated with apocynin (Apo, 100 mmol/l) or
rotenone (ROT, 10mmol/l) for 30min, and then stimulated by 100 nmol/l Aldo for further 2 h in the presence of DCF. DCF fluorescence was
detected by flow cytometry. (e) Mitochondrial ultrastructure morphology. Podocytes were treated with vehicle or Aldo for 24 h ( 50,000).
(f) Representative images of podocytes stained with JC-1. Podocytes were exposed to vehicle or Aldo for 24 h. (g) Aldo induced MtD in
podocytes. Podocytes were stimulated with the indicated concentrations of Aldo for 24 h. Mitochondrial membrane potential (MMP),
adenosine-50-triphosphate (ATP) content, and mitochondrial DNA (mtDNA) copy number were detected as described in Materials and Methods
section. Values represent the means±s.e.m. (n¼ 6). *Po0.01 vs. control. #Po0.01 vs. the Aldo-treated group. Cntl, control; rRNA, ribosomal RNA.
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production in a time-dependent manner that was noticeable
initially at 15min, maximal at 2 h, and sustained to 24 h
(Figure 1a and b). In addition, Aldo induced ROS production
in a dose-dependent manner with a noticeable effect at
50 nmol/l and a maximal effect at 100–200 nmol/l (Figure 1c).
The mitochondrial respiratory chain complex I inhibitor,
rotenone, but not the nicotinamide (NAM) adenine dinucleo-
tide phosphate oxidase inhibitor, apocynin, almost completely
blocked ROS production, which indicated that Aldo-induced
ROS production originated from the mitochondria (Figure
1d). Mitochondrial morphology was observed by transmission
electron microscopy. Swollen mitochondria with disorganized
and fragmented cristae were seen in podocytes treated with
Aldo for 24 h (Figure 1e). In consistent with mitochondrial
ultrastructural changes, JC-1 fluorescence detected by confocal
microscopy showed a reduction in red fluorescence accumu-
lated in the mitochondria and an increase in green
fluorescence distributed in the cytoplasm in podocytes treated
with Aldo for 24 h (Figure 1f), suggesting that Aldo induced
the reduction of MMP. This finding was confirmed by
quantitative analysis using flow cytometry. Similarly, Aldo
reduced ATP production, and mtDNA copy number in a
dose-dependent manner (Figure 1g).
It has been reported that Aldo contributes to cell injury. We
therefore examined whether Aldo induced podocyte injury. As
shown in Figure 2a and b, Aldo induced podocyte apoptosis in
a dose-dependent manner as assessed using Hoechst 33258
staining and annexin V/flow cytometry detection. Aldo
activated caspase-3 and -9, but not caspase-8 (Figure 2c),
which indicated that apoptosis in Aldo-induced podocytes was
mediated by the intrinsic mitochondria pathway. We also
investigated the effect of Aldo on the expression of the
glomerular slit diaphragm proteins, nephrin, and podocin.
Aldo significantly inhibited nephrin and podocin expression in
a dose-dependent manner (Figure 2d and e).
As both the MR and glucocorticoid receptor (GR) have
been reported to mediate the response of Aldo,16 we
characterized the role of each receptor using eplerenone
(EPL) and mifepristone (RU-486) as specific antagonists. As
shown in Figure 3a–c, the MR antagonist, EPL, abrogated
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Figure 2 |Aldosterone (Aldo)-induced podocyte injury. (a, b) Aldo-induced podocyte apoptosis. (a) Hoechst 33258 staining. Confluent
podocytes were exposed to vehicle or Aldo for 48 h. Arrow indicated apoptosis-induced chromatin condensation and fragmentation
( 200). (b) Quantification of apoptotic cells by flow cytometry. Podocytes were incubated with Aldo at the indicated concentrations
(0–100 nmol/l) for 48 h. (c) Caspase-3, -8, and -9 activities. Podocytes were treated as in b. (d) Real-time reverse transcriptase (RT)-PCR
analysis for nephrin and podocin expression. (e) Western blotting analysis for nephrin and podocin. The cells were treated with Aldo
(0–100 nmol/l) for 24 h. Left: representative immunoblots. Right: densitometric analysis. The data are expressed as the means±s.e.m. (n¼ 6).
*Po0.01 vs. control. Cntl, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Aldo-induced MtD, but the GR antagonist, RU-486, did not
have this effect. Similarly, EPL rather than RU-486 notably
inhibited the decrease in nephrin induced by Aldo (Figure
3d). These results strongly indicate that the stimulatory effect
of Aldo on MtD and podocyte injury was mediated via the
activation of MR.
Aldo suppressed SIRT1/PGC-1a activation
Given that PGC-1a is a major regulator on mitochondrial
function, we then tested the effect of Aldo on PGC-1a
expression. PGC-1a is described as a highly regulated protein
and its levels vary greatly among tissues and in changing
metabolic situations.17 It was therefore important to
determine if PGC-1a was present in the podocytes. Reverse
transcriptase-PCR and western blot analysis (Figure 4a)
showed that PGC-1a was expressed in kidney and podocytes.
We also detected the presence of PGC-1a protein in
podocytes by immunofluorescence. PGC-1a protein was
mainly distributed in the cytoplasm under normal physio-
logical conditions (Figure 4b). Moreover, Aldo treatment
reduced PGC-1a mRNA and protein expression in a dose-
dependent manner (Figure 4c and d). Several studies have
identified the genomic and nongenomic actions of Aldo.18 As
shown in Figure 4e, actinomycin D, an inhibitor of gene
transcription, prevented the inhibition of PGC-1a mRNA
expression by Aldo, which indicated that the Aldo-mediated
reduction in PGC-1a expression was mediated by a genomic
action. In addition, Aldo increased the acetylation levels of
PGC-1a after 3 h of treatment (Figure 4f).
Aldo also dose-dependently reduced SIRT1 mRNA and
protein expression levels (Figure 4g). The MR antagonist,
EPL, completely inhibited these decreases of SIRT1 and
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Figure 3 |Aldosterone (Aldo)-induced mitochondrial dysfunction (MtD) via mineralocorticoid receptor (MR). (a) Reactive oxygen
species (ROS) production. Confluent podocytes were pre-treated with eplerenone (EPL, 10 mmol/l) or RU-486 (20 mmol/l) for 30min, and then
stimulated by 100 nmol/l Aldo for further 2 h in the presence of dichlorofluorescein (DCF). DCF fluorescence was quantified by flow
cytometry. (b) Representative images of podocytes stained with JC-1 ( 200). (c) Effects of EPL and RU-486 on MMP, adenosine-50-
triphosphate (ATP) content, and mitochondrial DNA (mtDNA) copy number. (d) Western blotting analysis for nephrin expression. The
podocytes were pre-treated with EPL (10 mmol/l) or RU-486 (20mmol/l) for 30min, and then stimulated by 100 nmol/l Aldo for further 24 h.
Results are presented as means±s.e.m. (n¼ 6). *Po0.01 vs. vehicle group. #Po0.01 vs. the Aldo-treated group. Cntl, control.
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PGC-1a protein levels in Aldo-treated podocytes (Figure 4h),
further demonstrating that the effect of Aldo on podocytes
was mediated via the MR.
Suppression of endogenous PGC-1a expression induced MtD
and podocyte injury
Given the observation that Aldo-induced podocyte injury
via MtD was accompanied with a reduction in PGC-1a
expression, we tested the role of PGC-1a in mitochondrial
function and podocyte damage. PGC-1a expression was
inhibited (B85% reduction) by PGC-1a short hairpin RNA
(shRNA) (Figure 5a and b). As shown in Figure 5c and d,
downregulation of PGC-1a by shRNA reduced MMP (by
35%), ATP levels (by 55%), and mtDNA copy number (by
60%). Taken together, these effects provide strong evidence
that MtD occurred in podocytes after suppression of
endogenous PGC-1a expression.
We next examined whether MtD induced by knockdown
of PGC-1a resulted in podocyte injury. As shown in Figure 6,
PGC-1a shRNA increased the percentage of cells undergoing
apoptosis by 65%, and increased levels of caspase-3 and
-9 activity by 70% and 35%, respectively. PGC-1a shRNA
had no effect on caspase-8 activity. Moreover, nephrin and
podocin protein concentrations also decreased by 35%
and 25%, respectively, following knockdown of PGC-1a.
Therefore, we concluded that suppression of endogenous
PGC-1a expression induced MtD and podocyte injury.
PGC-1a overexpression inhibited Aldo-induced MtD and
podocyte injury
In contrast to PGC-1a deficiency, we next tested the role of
PGC-1a overexpression on Aldo-induced MtD and podocyte
injury using PGC-1a adenoviral vectors. Podocytes were
infected with Ad-PGC-1a that expressed murine PGC-1a at
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multiplicities of infection (MOI) 50. As shown in Figure 7a,
expression of PGC-1a was confirmed by western blotting
analysis of cell lysates prepared from the podocytes after
infection.
Podocytes infected with empty vector and then treated
with Aldo had swollen mitochondria with disorganized and
fragmented cristae. In contrast, typical mitochondria with
normal intact cristae and dense matrices were observed in
PGC-1a-overexpressed podocytes treated with Aldo (Figure
7b). Next, we investigated the role of PGC-1a on ROS
production. As shown in Figure 7c and d, Ad-PGC-1a
infection reduced the amount of ROS accumulation in Aldo-
treated podocytes. JC-1 fluorescence detected by confocal
microscopy showed that PGC-1a overexpression prevented
the transition from red fluorescence to green fluorescence
induced by Aldo (Figure 7e), suggesting that PGC-1a could
prevent the reduction of MMP. This finding was confirmed by
quantitative analysis using flow cytometry (Figure 7f).
Similarly, PGC-1a inhibited the decrease in ATP production
and mtDNA copy number induced by Aldo (Figure 7f). Taken
together, these observations indicated that overexpressed
PGC-1a prevented Aldo-induced MtD in podocytes.
It has been verified previously that endogenous PGC-1a
was relevant to cell survival. We therefore studied whether
PGC-1a overexpression conferred protection against Aldo-
induced podocyte injury. Effects of PGC-1a on cellular
apoptosis were determined by Hoechst 33258 staining and the
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labelling (TUNEL) assay (Figure 8a) and flow cytometry
(Figure 8c). We observed that PGC-1a-overexpressing cells
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were significantly more resistant to Aldo-induced apoptosis.
This finding supported the idea that PGC-1a expression
protected podocytes from Aldo-induced apoptosis. The
protective effect of PGC-1a on apoptosis prompted us to
investigate the roles of PGC-1a on the cytochrome c release
and the activity of caspase cascade. As shown in Figure 8b,
cytochrome c was released from the mitochondria after
exposure to 100 nmol/l Aldo, and PGC-1a overexpression
blocked the release of cytochrome c. The activation of
caspase-3 and -9 was monitored in podocytes, and PGC-1a
reduced the activation of both caspase-3 and -9 (Figure 8d).
These results indicated that PGC-1a could protect podocytes
from Aldo-induced apoptosis by preventing the activation of
the mitochondrial apoptotic cascade. Moreover, PGC-1a
overexpression inhibited Aldo-induced reduction of nephrin
and podocin, the podocytic phenotypic markers, as assessed
by real-time PCR and immunoblotting (Figure 8e and f).
Thus, PGC-1a overexpression inhibited Aldo-induced podo-
cyte injury by inhibiting MtD.
SIRT1 overexpression prevented Aldo-induced MtD and
podocyte injury
As SIRT1 regulates PGC-1a activity, we further investigated
the role of SIRT1 in Aldo-induced MtD and podocyte injury.
We observed a dose-dependent induction of SIRT1 protein
levels in podocytes infected with Ad-SIRT1 vectors. Ad-SIRT1
at multiplicities of infection of 50 induced greater than a
threefold increase in SIRT1 expression (Figure 9a). Overexpression
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of SIRT1 increased the expression of PGC-1a mRNA and
protein (Figure 9b and d) in a dose-dependent manner.
TFAM, a nuclear-encoded mitochondrial transcription factor
that is needed for the expression of key mitochondrial-
encoded genes and is a downstream target of PGC-1a, was
also increased (Figure 9d). Moreover, knockdown of PGC-1a
by shRNA abolished the upregulation of TFAM induced by
SIRT1 (Figure 9e).
The mechanism that links SIRT1 and PGC-1a was further
examined. SIRT1 appears to regulate PGC-1a expression at
the transcriptional level, as SIRT1 increased PGC-1a
promoter activity in a dose-dependent manner when assessed
using a luciferase reporter system (Figure 9c). Furthermore,
PGC-1a could also be regulated at the post-translational
level, as we observed that Aldo-induced PGC-1a acetylation
was decreased in the SIRT1-overexpressed group (Figure 9f).
We measured MMP, ATP content, and mtDNA copy
number to evaluate the hypothesis that SIRT1 overexpression
prevents Aldo-induced MtD via PGC-1a. SIRT1 overexpres-
sion prevented the Aldo-induced reduction in MMP, ATP
production, and mtDNA copy number. Knockdown of PGC-
1a, using PGC-1a shRNA, abolished these protective effects
(Figure 9g).
We then tested the hypothesis that SIRT1 overexpression
protected against Aldo-induced podocyte injury via PGC-1a.
As shown in Figure 10a, SIRT1 overexpression decreased
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Aldo-induced apoptosis, and this effect was abolished by
knockdown of PGC-1a. In addition, SIRT1 overexpression
restored nephrin and podocin mRNA and protein levels after
Aldo treatment. Also PGC-1a shRNA blocked the protective
effect of SIRT1 (Figure 10b and c). Taken together, SIRT1
inhibited Aldo-induced MtD and podocyte injury by
regulating PGC-1a activity at both the transcriptional and
post-translational levels.
RSV attenuated Aldo-induced MtD and podocyte injury
To consolidate our hypothesis that SIRT1 conferred protec-
tion against Aldo-induced MtD and podocyte injury, we
further investigated the effect of the SIRT1 activator RSV on
Aldo-induced MtD and podocyte injury. As shown in Figure
11a–c, RSV reduced Aldo-induced podocyte apoptosis in a
dose-dependent manner and restored nephrin and podocin
mRNA and protein expression. These effects were blocked by
the SIRT1 inhibitor NAM. In addition, the SIRT1 targets,
PGC-1a and TFAM, were upregulated following RSV
treatment. NAM also abolished the effects of RSV on these
genes (Figure 11b and c). Furthermore, RSV decreased Aldo-
induced PGC-1a acetylation, which was blocked by NAM
(Figure 11d). RSV blocked the Aldo-induced MtD at the dose
range (10–50 mmol/l), similar to the effect of RSV on Aldo-
induced podocyte injury, and NAM abolished the role of RSV
in inhibiting Aldo-induced MtD (Figure 10e). These tests
supported the hypothesis that RSV attenuated Aldo-induced
MtD and podocyte injury through SIRT1 activation.
RSV protected mitochondrial function and podocytes in
Aldo-treated mice
Finally, we sought in vivo support for the protective effect of
RSV on mitochondrial function and podocytes by studying
mice that had been treated with Aldo for 14 days. The Aldo
infusion induced a 50-fold elevation of plasma Aldo levels
compared with 668.29±53.41 pmol/l in controls. Aldo also
increased the renal weight/body weight ratio and decreased
serum potassium levels (Table 1). We quantified the level of
podocyte apoptosis using double immunofluorescence label-
ling, including synaptopodin and the TUNEL assay in sham
and Aldo-infused mice. The overlap of nuclear 4,6-diamidi-
no-2-phenylindole (blue) and TUNEL labelling (green) in the
presence of cytoplasmic synaptopodin labelling (red) was
scored as apoptotic podocytes. TUNEL-positive podocytes per
glomerular cross-section were significantly increased in Aldo-
infused mice compared with the sham group (Figure 12). The
systolic blood pressure was measured in conscious mice using
the Visitech tail cuff system (BP 2000 Blood Pressure Analysis
System, Visitech). Aldo failed to increase systolic blood
pressure, and RSV treatment did not influence blood pressure
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in control or Aldo-infused mice (data not shown). Then we
examined the kidneys of these mice histopathologically.
Aldo treatment resulted in glomerular enlargement and
increased mesangial area, and RSV restored the normal
structure of the glomeruli (Figure 13a). Moreover, albumi-
nuria was significantly reduced by RSV treatment in Aldo-
infused mice (Figure 13b). In electron micrographs, extensive
fusion of foot processes was evident and the width of
podocyte filtration slits was decreased in Aldo-treated mice. In
contrast, treatment of the Aldo-infused mice with RSV
maintained the normal shape of the foot processes and
restored the podocyte slit width (Figure 13c and d). As shown
in Figure 13e and f, RSV restored nephrin and podocin
mRNA and protein levels. Similarly, SIRT1, PGC-1a, and
TFAM were significantly induced on RSV treatment, which
also translated into the increase in proteins levels. Further-
more, we observed that acetylated PGC-1a was increased in
Aldo-infused mice, and that RSV treatment decreased PGC-
1a acetylation (Figure 13g).
We then examined the effect of RSV treatment on
mitochondrial function. As shown in Figure 14a, RSV
treatment in Aldo-infused mice reduced mitochondrial
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acetylation. (e) Mitochondrial membrane potential (MMP), adenosine-50-triphosphate (ATP) production and mtDNA copy number. Results
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Table 1 | Biological parameters in Aldo- or vehicle-infused
mice at 2 weeks
Vehicle (n=8) Aldo (n=8)
Body weight, g 28.75±1.24 27.98±1.03
Kidney weight/body weight
ratio, mg/g
12.23±0.27 13.77±0.54*
Serum K+, mmol/l 3.69±0.18 3.09±0.03*
Serum Na+, mmol/l 152.60±1.67 153.80±2.49
Plasma Aldo, pmol/l 668.29±53.41 34872.65±491.58*
Abbreviation: Aldo, aldosterone.
*Po0.05 vs. vehicle mice.
Data are represented as mean±s.e.m.
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swelling as compared with the Aldo-infused mice without RSV
treatment. Also, RSV treatment rescued the MMP, ATP levels,
and mtDNA copy number in Aldo-infused mice (Figure 14b).
RSV protection against Aldo-induced MtD was further
confirmed by measuring mitochondrial respiratory chain
enzyme activities. As shown in Figure 14c, RSV treatment
restored the activities of complexes I, III, and IV. In contrast,
no changes in complex II activity were observed both in Aldo-
infused mice and in Aldo-infused mice treated with RSV.
We designed a series of studies (Figure 14d) to assess the
effect of RSV on oxidative stress induced by Aldo.Urinary
F2-isoprostane levels, an indicator of renal ROS production,
were increased in Aldo-infused mice, but were improved in
the RSV-treatment group. Malondialdehyde levels, the
indicator used to assess the pro-oxidative status in kidneys,
paralleled F2-isoprostane concentrations among the three
groups. We assessed ROS production in the kidneys through
dichlorofluorescein staining to confirm that the ROS levels
were of renal origin. These findings indicated that RSV
treatment in Aldo-infused mice abolished the induction of
ROS in glomeruli. Similar results were observed in mito-
chondria isolated from glomeruli. Therefore, these results
suggest that RSV protects podocytes in Aldo-induced mice by
regulating mitochondrial function.
DISCUSSION
As shown previously, podocyte loss occurs in several
glomerular diseases, including immunoglobulin A nephro-
pathy, lupus nephritis, focal segmental glomerulosclerosis,
and diabetic nephropathy.2 Recent studies using murine
models of diabetes mellitus suggest that the apoptosis of
podocytes leads to a reduction in the cell density.19 Aldo has
recently attracted considerable attention for its involvement
in the pathophysiology of kidney failure, in which apoptotic
cell loss has a critical role. Aldo has been shown to cause
tubular epithelial cell apoptosis, and this effect has been attri-
buted to the dephosphorylation of cytosolic phospho-Bad
and associated accumulation of cytosolic cytochrome c.20
Similarly, Mathew et al.21 demonstrated that Aldo causes
mesangial cell apoptosis by affecting the mitochondrial apoptotic
pathway. Aldo has also been shown to induce podocytes
apoptosis,22 which is consistent with our studies. Meanwhile,
in the present study, podocyte apoptosis induced by Aldo was
accompanied by the loss of two silt diaphragm proteins,
nephrin and podocin, which have crucial roles in the func-
tion of the glomerular filtration barrier.23 In addition, our
findings demonstrated that SIRT1/PGC-1a axis activation
protected against Aldo-induced podocytes injury, by inhibit-
ing both cell apoptosis and loss of slit diaphragm proteins.
Aldo may cause various physiological effects through both
genomic and nongenomic mechanisms.24 The classical
genomic pathway of Aldo action are mediated through
binding to cytosolic MR and subsequent translocation to the
nucleus, leading to changes in the transcription and
translation of effector proteins. Aldo also exerts rapid, non-
genomic effects in a cell-specific manner that induce
the activation of intracellular signalling pathways,
including mitogen-activated protein kinase, Rho-kinase,
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phosphatidylinositol 3-kinase (PI3K), and protein kinase C.
In the present study, the reduction in PGC-1a expression
caused by Aldo was blocked by actinomycin D and EPL,
indicating that the response to Aldo is a classic genomic
action. Aldo has high affinity for MR, a much lower affinity
for GRs, and negligible affinity for other nuclear transactivat-
ing factors. Previous studies have shown that treatment with
EPL significantly reduced intrarenal ROS and attenuated
podocyte injury and proteinuria in Aldo-infused rats.25 It has
also been reported that the Aldo-induced activation of its
target proteins is mediated by GR.26 Our study showed that
Aldo-induced MtD was inhibited by a MR antagonist and
unaffected by the GR antagonist, which supports a MR-
dependent mechanism.
MtD has been shown to contribute to podocyte injury.27,28
To evaluate mitochondrial function, we selected a group
of indicators, such as mitochondrial morphology, MMP, ATP
production, and mtDNA copy number. Recently, MMP
collapse has been shown to have an essential role in media-
tion of apoptosis, in that it allows the release of apoptotic
mediators, such as cytochrome c and apoptosis-inducing
factor, into the cytoplasm.29 The disruption in MMP led to
cytochrome c release, activation of caspase-9, and subse-
quently the death of proximal tubule cells after treatment
with albumin.30 Chen et al.31 found that the loss of MMP was
an early event in S-(1,2-dichlorovinyl)-L-cysteine-treated
proximal tubule epithelial cells and occurred before cyto-
chrome c release. Second, mitochondria are the energy
powerhouses of cells and make the most use of the cell’s ATP,
utilizing oxidative phosphorylation. The kidney consumes a
large amount of energy supplied as ATP, so any disruption
in this supply is likely to cause renal dysfunction.4 Indeed,
ischemic injury produced by intracellular ATP depletion has
been shown to induce apoptosis in the porcine proximal
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tubule epithelial cell line LLC-PK1,32 and in primary culture
of mouse proximal tubule cells.33 In addition, mitochondrial
biogenesis is a complicated process that requires the syn-
thesis, import, and incorporation of proteins and lipids, as
well as the replication of mtDNA.34 Some investigators have
speculated that mtDNA copy number might be a surrogate
marker of mitochondrial function.35 Indeed, a case–control
study found that a higher mtDNA copy number among end-
stage renal disease patients on maintenance hemodialysis was
associated with a better survival rate.36 Moreover, MtD could
be caused directly by changes in matrix volume, and mitochon-
drial swelling can be an important clue for the mechanism of
apoptosis, because it may cause inner membrane disrup-
tion and release of mitochondrial proapoptogenic factors.37
Our findings demonstrate that SIRT1/PGC-1a inhibited
MtD by sustaining MMP, enhancing the production of
ATP, upregulating mtDNA copy number, and preventing
mitochondrial swelling. Endogenous PGC-1a was found to
be essential for the maintenance of mitochondrial function
under normal conditions. Furthermore, MtD occurred before
podocyte apoptosis, after Aldo treatment or after PGC-1a
shRNA transfection. Therefore, all these data indicate that
MtD is involved in Aldo-induced podocyte injury, that
PGC-1a silencing induced podocyte injury by disrupting
mitochondrial function, and that SIRT1/PGC-1a inhibited
Aldo-induced podocyte injury by blocking MtD.
ROS have a key role in the progression of renal injury.38 In
recent years, it has become clear that one of the most important
pathways by which Aldo exerts its negative effects on the kidney
is through production of ROS. Patni et al.20 demonstrated that
diphenyleneiodonium, an inhibitor of NAM adenine dinucleo-
tide phosphate oxidase, partially attenuated Aldo-induced
tubule cell apoptosis. A previous study from our group found
that two major sources of ROS in response to Aldo were
mitochondria and NAM adenine dinucleotide phosphate
oxidase in mesangial and proximal tubule epithelial cells.39 It
has been shown previously that the excessive production of
ROS in mitochondria will damage lipids, proteins, and mtDNA
and will result in cell damage,40 which prompted us to test the
origin of ROS in Aldo-induced podocyte injury. Our study
showed that Aldo induced both mitochondrial ROS produc-
tion and MtD in podocytes, indicating that ROS that
originated from mitochondria and MtD are involved in
Aldo-induced podocyte injury.
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PGC-1 coactivators are important regulators of mitochon-
drial biogenesis in response to changing conditions external
to the cell or organism. Anderson et al.41 found that increased
copies of PGC-1a were sufficient to exert an effect on
mitochondrial function through increase in MMP in mouse
fibroblasts. Valle et al.42 reported that PGC-1a could inhibit
MtD by preventing the loss of MMP in vascular endothelial
cells. The regulation by PGC-1a on ATP synthesis and
mtDNA copy number was also reported in cultured cardiac
myocytes.43 In agreement with these findings, our data
showed that overexpression of PGC-1a prevented Aldo-
induced reduction of MMP, ATP content, and mtDNA copy
number. In addition, our findings also showed that knock-
down of endogenous PGC-1a could induce MtD, as
demonstrated by a decrease in MMP, ATP production, and
mtDNA copy number.
This present study demonstrated that SIRT1 activated
transcriptional activity of PGC-1a by targeting the promoter
region in podocytes and thus blocked Aldo-induced MtD and
podocyte injury. As recently reviewed, PGC-1a activity is not
only determined by its expression levels, but also by a
number of post-translational modifications such as phos-
phorylation, acetylation, and methylation. These modifica-
tions are involved in the regulation of the PGC-1a target
genes by affecting the intrinsic activity or the stability of
the PGC-1a protein.44 Our results showed first that SIRT1
and PGC-1a interact physically and second that SIRT1
regulated PGC-1a acetylation. Several studies with similar
findings have led to the conclusion that SIRT1 exerts its
control over mitochondrial number and oxidation primarily
by regulating PGC-1a activity in other cells. In skeletal muscle,
deacetylation of PGC-1a by SIRT1 promotes transcription of
mitochondrial fatty acid oxidation genes.45 Overexpression
of SIRT1 deacetylase activated the transcriptional activity of
PGC-1a in neuron metabolism, as well as in mitochondrial
activity.44 Although the finding of a link between SIRT1 and
PGC-1a represented a promising breakthrough in our under-
standing of how the cell regulates mitochondrial function
transcriptionally, the link between these proteins was not clear.
Chen et al.46 found that the SIRT1/PGC-1a axis is not likely to
respond similarly in all tissues on energy stress. Moreover,
PGC-1a activity was inhibited by SIRT1 in the PC12 adrenal
cell line.47 Our current study confirmed that the blocking
effect of SIRT1 on Aldo-induced MtD and podocyte injury
was PGC-1a dependent, as PGC-1a shRNA abolished this
SIRT1 blocking effect. Despite this finding, we cannot exclude
unequivocally that PGC-1a is the sole target of SIRT1, as
SIRT1 regulates other substrates.48
RSV is a polyphenol that is enriched in the skins of red
grapes. Although most studies have focused on the beneficial
effects of RSV in the prevention of coronary heart diseases
and cancer, reports that consider its possible use as a
therapeutic agent in treating kidney diseases are quite limited.
Ignatowicz and Baer-Dubowska49 found that RSV could
inhibit the generation of free radicals by scavenging ROS
and chelating iron, thereby attenuating the inflammatory
process and minimizing renal damage. A recent study
found that RSV inhibits renal fibrosis in the obstructed
kidney through deacetylating Smad3.50 Our study found
that RSV conferred protection against Aldo-induced MtD
and podocyte injury both in cultured podocytes. We next test
whether the phenomenon observed in cell culture models
indeed occurred in vivo. It is known that standard unine-
phrectomied Aldo/salt or deoxycorticosterone acetate-salt
models develop hypertension and podocyte damage.51 A
limitation of these models, however, is that they are associated
with severe hypertension, which may represent a confounding
factor affecting kidney injury. In the present study, we for
the first time describe a simple kidney injury model with
Aldo infusion only without uninephrectomy or high salt.
Owing to the lack of obvious hypertension, this new
model will be better suited for investigation of the direct
action of Aldo in settings of CKD. RSV significantly reduced
the levels of oxidative stress in Aldo-infused mice. Moreover,
although several studies have demonstrated that RSVexerts its
role by activation of nicotinamide adenine dinucleotide-
dependent deacetylase SIRT1,15,52 the idea that RSV is a
SIRT1 activator has been questioned. A number of recent
studies have shown that RSV regulated many of the biological
events such cell growth, glucose homeostasis, and protection
of the cardiovascular system via a SIRT1-independent
mechanism.53,54 Our results showed that the protective effect
of RSV on mitochondrial function and podocytes could be
abolished by the SIRT1 inhibitor, NAM, suggesting that this
process of RSV was SIRT1-dependent in our model.
In summary, our results showed that Aldo-induced MtD
and podocyte injury. PGC-1a was expressed in podocytes
and levels were reduced by Aldo. Suppression of endogenous
PGC-1a resulted in MtD and then podocyte injury. In
contrast, overexpression of PGC-1a could prevent Aldo-
induced MtD and podocyte injury. Furthermore, we found
that SIRT1 deacetylase activated the transcriptional activity of
PGC-1a and then prevented MtD and podocyte injury, a
finding that was also verified by RSV treatment in vivo and
in vitro. These findings provide new insights into the
pathogenic process of Aldo-induced podocyte injury and
also identify a new therapeutic target of SIRT1/PGC-1a
agonists for glomerular diseases.
MATERIALS AND METHODS
Reagents and antibodies
Aldo, apocynin, rotenone, EPL, RU-486, actinomycin D, RSV, NAM,
and anti-cytochrome c antibodies were purchased from Sigma (St
Louis, MO). Antibody against PGC-1a and horseradish peroxidase-
conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-nephrin and anti-podocin
antibodies were obtained from Abcam (Cambridge, MA). Anti-SIRT1,
anti-Flag, anti-TFAM, anti-COX IV, and anti-b-actin antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
Animals
Study protocols were reviewed and approved by the Institutional
Animal Care and Use Committee at Nanjing Medical University,
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China. In brief, 8-week-old C57BL/6J mice, weighing 25–30 g, had
osmotic minipumps implanted subcutaneously by an incision of the
right flank region under light 3% isoflurane anesthesia. Pumps
delivered a continuous infusion of Aldo (0.5 mg/h) (Alzet, Durect,
Cupertino, CA). Sham-operated mice served as the controls. After 7
days, Aldo-infused mice received vehicle or RSV (400mg/kg dose in
diet) for 14 days. All mice were maintained on a 12-h light–dark
cycle in a temperature-controlled (19–21 1C) room and were fed
standard rodent chow containing 0.5% NaCl.
Cell culture and virus infection
MPC5 conditionally immortalized mouse podocyte clonal cells
(kindly provided by Peter Mundel at Mount Sinai School of
Medicine through Dr Jie Ding at Peking University) were cultured
and induced to differentiate as described previously.55 Podocytes
were maintained without interferon-g at 37 1C for 14 days before
experimentation to induce differentiation. Adenoviral vectors
encoding FLAG-tagged mouse PGC-1a (Ad-PGC-1a) and SIRT1
(Ad-SIRT1) were obtained from Addgene (Cambridge, MA).
Lentivirus expressing shRNA for PGC-1a were from Santa Cruz
Biotechnology. Cells were infected with adenoviruses or lentiviruses
for 24 h before the experiments as described previously.56
Luciferase reporter assay
The PGC-1a promoter luciferase plasmid and the internal control
plasmid pCMV-Lac (Promega, Madison, WI) were co-transfected
into podocytes. Luciferase and b-galactosidase activities were mea-
sured on a microplate reader using 50 ml of each cell lysate (Bio-Rad,
Hercules, CA), and the luciferase activity was determined by
normalizing values to total protein levels and to b-galactosidase
activity.
Apoptosis analysis
Hoechst 33258 staining. Podocytes were grown on glass cover
slips for measurement of apoptosis. After treatment, podocytes
were stained with Hoechst 33258 and viewed by fluorescence
microscopy.
Annexin V-fluorescein isothiocyanate conjugated with propi-
dium iodide staining. After treatment, podocytes were seeded into
six-well plates and apoptosis was quantified by flow cytometry using
annexin V-fluorescein isothiocyanate and propidium iodide double
staining (annexin V:fluorescein isothiocyanate apoptosis detection
kit, BD Biosciences, San Diego, CA), according to the manufac-
turer’s instructions.
TUNEL assay in cultured podocytes. Apoptotic cell death was
determined using TUNEL staining with an In Situ Cell Death
Detection Kit (Roche Molecular Biochemicals, Mannheim, Ger-
many), following the manufacturer’s protocol. Morphological
changes in podocytes undergoing apoptosis were then detected by
counterstaining them with Hoechst 33258. The slides were examined
by confocal microscopy.
Analysis of podocyte apoptosis in renal tissue. Apoptotic cells
were detected on frozen kidney section using a fluorescein
isothiocyanate-labelled in situ TUNEL assay (Roche Molecular
Biochemicals) following the manufacturer’s protocol. For the
identification of apoptotic podocytes, tissue sections were co-
stained with 4,6-diamidino-2-phenylindole (blue), anti-synaptopo-
din antibody (red) and TUNEL (green). The cells labelled by 4,6-
diamidino-2-phenylindole, synaptopodin and TUNEL were counted
as apoptotic podocytes.
Detection of cytochrome c release from mitochondria
To measure the release of cytochrome c from mitochondria
following treatment with Aldo, podocytes were treated with Aldo
(100 nmol/l) for 48 h, harvested by gentle scraping, and washed once
with ice-cold phosphate-buffered saline. To obtain the mitochon-
drial fraction, cells were harvested, washed, and prepared using a
Mitochondria Isolation Kit (Pierce, Rockford, IL), following the
manufacturer’s instructions. The pellet obtained was defined as
the mitochondrial fraction and the supernatant as the cytosolic,
mitochondria-free fraction. Western blot was performed for both
cytoplasmic protein and mitochondrial protein to study the
possible release of cytochrome c from the mitochondria into the
cytoplasm.
Measurement of caspase-3, -8, and -9 activities
Caspase-3, -8, and -9 activities in podocytes were measured using
a caspase activity assay kit (Beyotime, Beijing, China) through
cleavage of a colorless substrate specific for caspase-3 (Ac-DEVD-
p-nitroaniline (pNA)), caspase-8 (Ac-IETD-pNA), or caspase-9
(Ac-LEHD-pNA) and release of the chromophore, pNA. The
absorbance of pNA was determined at 405 nm.
Immunofluorescence analysis
Cells on coverslips were fixed with 4% paraformaldehyde, permea-
bilized with 0.1%. Triton X-100, incubated with antibodies against
PGC-1a, blocked with 2% bovine serum albumin in phosphate-
buffered saline, and then incubated with Alexa fluor 555-conjugated
goat anti-rabbit immunoglobulin G. Nuclei were stained with
Hoechst 33258. After washing, coverslips were mounted and viewed
using an inverted fluorescence microscope.
Isolation of glomeruli and glomerular mitochondria
Isolation of glomeruli was performed as previously reported.57
Mitochondria from glomeruli were isolated using a kit purchased
from Sigma (MITO-ISO1, Sigma Chemical, St Louis, MO) using the
manufacturer’s protocol. Isolated mitochondria were resuspended in
storage buffer and the protein concentration determined by the
Bradford method.
Quantitative real-time PCR and reverse transcriptase-PCR
Total DNA and RNA from cultured podocytes and isolated
glomeruli were extracted by DNeasy Tissue Kit (QIAGEN Sciences,
Germantown, MD) and Trizol reagent (Invitrogen, Carlsbad, CA),
respectively. Oligonucleotides were designed using the Primer3
software (available at http://frodo.wi.mit.edu/) and synthesized at
Invitrogen. The sequences of primer pairs are shown in Table 2.
Real-time PCR was used to detect mtDNA copy number, and real-
time reverse transcription-PCR was used to determine the target
gene expression. Reverse transcription was performed using a
reaction kit (Promega Reverse Transcriptase System) according to
the manufacture’s protocol. Real-time PCR amplification was
performed using the ABI 7300 Real-time PCR Detection System
(Foster City, CA) with the SYBR Green master mix (Applied
Biosystems, Foster City, CA). Cycling conditions were 95 1C for
10min followed by 40 repeats of 95 1C for 15 s and 60 1C for 1min.
Relative amounts of mtDNA copy number were normalized to 18S
ribosomal RNA levels encoded by the nuclear DNA, and mRNA
values were normalized to the glyceraldehyde 3-phosphate dehy-
drogenase gene control values and calculated using the comparative
cycle threshold (DDCt) method.
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Western blotting
Podocytes or isolated glomeruli were lysed in protein lysis buffer
(50mmol/l Tris, 150mmol/l NaCl, 10mmol/l EDTA, 1% Triton X-
100, 200mmol/l sodium fluoride, 4mmol/l sodium orthovanadate
as protease inhibitors, pH 7.5) for 15min on ice. Protein concen-
tration was measured as above. Immunoblotting was performed
with primary antibodies against PGC-1a (1:200), acetylated PGC-1a
(1:1000), SIRT1 (1:1000), FLAG (1:1000), TFAM (1:1000), nephrin
(1:200), podocin (1:500), (1:200), cytochrome c (1:1000), COX IV
(1:1000), or b-actin (1:1000), followed by the addition of horse-
radish peroxidase-labelled secondary antibodies. The blots were
visualized with Amersham ECL Detection Systems (Amersham,
Buckinghamshire, UK). Densitometric analysis was performed using
Quantity One Software (Bio-Rad).
Mitochondrial membrane potential
The MMP of podocytes and isolated mitochondria were monitored
using JC-1, a MMP-sensitive fluorescent dye, as described
previously.58 Briefly, the isolated mitochondrial pellet and disso-
ciated podocytes were washed twice with Hank’s balanced salt
solution (Sigma), and incubated in the dark with JC-1 (7.5 mmol/l;
30min at 37 1C). Mitochondria and cells were washed with JC-1
washing buffer, and fluorescence was detected by fluorescence-
assisted cell sorting for podocytes, or a FLUOstar Optima reader
(BMG LABTECH, Ortenberg, Germany) for isolated mitochondria.
The relative MMP was calculated using the ratio of J-aggregate/
monomer (590/520 nm). Values are expressed as the fold-increase in
J-aggregate/monomer fluorescence over control cells.
ATP content measurement
ATP levels were determined in the podocytes or isolated glomeruli
with a luciferase-based bioluminescence assay kit (Sigma-Aldrich,
St Louis, MO) in a FLUOstar Optima reader according to the
manufacturer’s instructions. Total ATP levels were the results of the
luminescences normalized by protein concentrations.
Mitochondrial complexes enzyme activity assay
Complexes I, II, and IV enzyme activities of isolated mitochondria
were measured using microplate assay kits purchased from
Mitosciences according to the protocols of the manufacturer. To
determine the activity of mitochondrial complex I, the microplate
assay kit for complex I activity (MS141, Mitosciences, Eugene, OR)
was used. The enzyme is immunocaptured within the wells of the
microplate and its activity is determined by following the oxidation
of NADH to nictonamide adenine dinucleotide and the simulta-
neous reduction of a dye, which leads to increased absorbance at
450 nm. The Complex II Microplate Assay Kit (MS241, Mitos-
ciences) determined the activity of succinate decylubiquinone
dichloroindophenol oxidoreductase by following reduction of ubiqui-
none to ubiquinol was measured by a decrease in absorbance at
600nm. The Complex IV Microplate Assay Kit (MS444, Mitosciences)
determined the oxidation of reduced cytochrome c by the absorbance
change at 550 nm. The enzyme activities of mitochondrial complex III
were assessed spectrophotometrically using the Complex III Assay Kit
according to the manufacturer’s manual (Genmed Scientifics,
Shanghai, China). Complex III-linked ubiquinol cytochrome c
reductase activity was determined by monitoring the reduction of
cytochrome c by the electrons donated from ubiquinol, which can be
monitored at 550 nm. Enzymatic activities are expressed as nanomoles
per minute per milligram of protein.59
Assessment of ROS production
Podocyte ROS production was measured as previously described.39
For measurement of isolated glomeruli and mitochondrial ROS
levels, isolated glomeruli and mitochondria were firstly resuspended
in Krebs–Henseleit bicarbonate-buffered solution and HEPES–saline
buffer, pH 7.4 (10mmol/l HEPES, 140mmol/l NaCl, 5mmol/l KCl,
1.2mmol/l Na2HPO4, 5mmol/l NaHCO3, 6mmol/l glucose,
1mmol/l MgCl2, 2mmol/l CaCl2), respectively, and then incubated
with dichlorodihydrofluorescein diacetate at a final concentration of
10 mmol/l for 10min. The fluorescence intensity was analyzed on a
FLUOstar Optima reader at excitation/emission wavelengths of 485/
535 nm. Data are expressed as fluorescence units per mg protein.
PGC-1a acetylation
PGC-1a acetylation was determined by immunoprecipitation of 2mg
of protein lysate in lysis buffer using an antibody against PGC-1a.
Levels of acetylated PGC-1a were subsequently assessed with an
anti-acetyl lysine antibody (Cell Signaling Technology). When indi-
cated, 10mmol/l NAM was added for the last 15 h before harvest.
Kidney histopathological analysis
Harvested tissues from mice were fixed with 4% paraformaldehyde,
embedded in paraffin, and sectioned transversely. Kidney sections
(3mm) were stained with periodic acid–Schiff or hematoxylin–eosin.
All sections were examined by person without knowledge of the
treatment protocol.
Transmission electron microscopy
To evaluate the mitochondrial and podocyte morphology, podocytes
and kidney cortex were collected, fixed in 1.25% glutaraldehyde/
0.1mol/l phosphate buffer, and postfixed in 1% OsO4/0.1mol/l
phosphate buffer. Ultrathin sections (60 nm) were cut on a micro-
tome, placed on copper grids, stained with uranyl acetate and lead
Table 2 | Primer sequences for real-time RT-PCR
Gene symbol Accession number Forward primer (50–30) Reverse primer (50–30)
PGC-1a NM_008904 CGGAAATCATATCCAACCAG TGAGGACCGCTAGCAAGTTTG
Nephrin NM_019459 TTCAGACCACACCAACATCC AGCCAGGTTTCCACTCCA
Podocin NM_130456 GTGAGGAGGGCACGGAAG AGGGAGGCGAGGACAAGA
TFAM NM_009360 GTCGCATCCCCTCGTCTATC CCTCCTTCTCCATACCCATC
SIRT1 NM_019812 CAGTGTCATGGTTCCTTTGC CACCGAGGAACTACCTGAT
mtDNA NC_005089 ATCCTCCCAGGATTTGGAAT ACCGGTAGGAATTGCGATAA
18S rRNA X00686 TTCGGAACTGAGGCCATGATT TTTCGCTCTGGTCCGTCTTG
GAPDH NM_008084 GTCTTCACTACCATGGAGAAGG TCATGGATGACCTTGGCCAG
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mtDNA, mitochondrial DNA; PGC-1a, peroxisome proliferator-activated receptor-g coactivator 1a; rRNA,
ribosomal RNA; RT-PCR, reverse transcriptase-PCR; SIRT1, silent mating type information regulation 2 homolog 1; TFAM, mitochondrial transcription factor A.
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citrate, and examined in an electron microscope (JEOL JEM-1010,
Tokyo, Japanesis). The width of podocyte filtration slits was
measured as previously described.60
Measurement of malondialdehyde concentration
Renal cortex malondialdehyde levels were analyzed in tissue
homogenates after precipitation of protein with trichloroacetic acid.
Thiobarbituric acid reacts with malondialdehyde in acidic medium
at 95 1C for 30min to form a thiobarbituric acid reactive product.
The absorbance of the resultant pink product can be measured at
534 nm.
Urine analysis of albumin and F2-isoprostanes excretion
Urinary concentrations of albumin and F2-isoprostane were
determined using enzyme-linked immunosorbant assay (EIA) kits
from Exocell (Philadelphia, PA) and Cayman (Ann Arbor, MI),
respectively. Samples were run in duplicate and results averaged for
all assays.
Statistical analysis
The data shown represent means±s.e.m. Statistical analysis used one-
way analysis of variance followed by Bonferroni correction using SPSS
11.5 statistical software (SPSS, Chicago, IL). A value of Po0.05 was
considered to be significant.
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